• Merit Medical Systems recently announced that Sheri Lewis, a veteran operations executive with three decades of experience at companies including Medtronic and Honeywell, joined as Executive Vice President of Global Operations on August 31, 2026.
• The planned handover, with long-serving COO Mr. Peterson remaining as Senior Advisor until March 5, 2027, underscores the company’s emphasis on maintaining operational continuity while refreshing its leadership bench.
• Next, we’ll examine how bringing in Sheri Lewis to oversee global operations could influence Merit Medical’s existing investment narrative.

Outshine the giants: these 17 early-stage AI stocks could fund your retirement.

Merit Medical Systems Investment Narrative Recap

To own Merit Medical, you need to believe it can keep expanding its higher margin therapeutic platforms while managing reimbursement, tariff and China headwinds. The Sheri Lewis appointment looks supportive of execution and supply chain resilience rather than a material shift in the near term WRAPSODY reimbursement catalyst or the biggest risks around tariffs and APAC demand, so its immediate impact on those issues appears limited.

The most relevant recent announcement here is Merit's July 2026 guidance raise, with 2026 revenue now expected between US$1.631 billion and US$1.643 billion after stronger first half results. That outlook was set before Lewis was named EVP of Global Operations, so investors may watch whether her manufacturing and supply chain background helps the company stay within that range while also dealing with ongoing recalls, tariff costs and rising operating expenses.

Yet beneath the leadership change, investors should be aware that tariff exposures and China volume pressures could still...

Merit Medical Systems' narrative projects $1.9 billion revenue and $226.4 million earnings by 2029. This requires 6.3% yearly revenue growth and about a $80.8 million earnings increase from $145.6 million today.

Uncover how Merit Medical Systems' forecasts yield a $100.27 fair value, a 9% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were already modeling revenue of about US$1.9 billion and earnings near US$223 million by 2029, which assumes smooth acquisition integration and robust uptake of newer platforms compared with the baseline narrative that leans more heavily on execution risks and reimbursement delays; after this leadership news, you may find that these different viewpoints on Merit's path become even more important to compare.

Explore 2 other fair value estimates on Merit Medical Systems - why the stock might be worth as much as 29% more than the current price!

The Verdict Is Yours

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Merit Medical Systems research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Merit Medical Systems research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Merit Medical Systems' overall financial health at a glance.

Want Some Alternatives?

Our top stock finds are flying under the radar-for now. Get in early:

• Invest in the nuclear renaissance through our list of 92 elite nuclear energy infrastructure plays powering the global AI revolution.
• Uncover the next big thing with 21 elite penny stocks that balance risk and reward.
• AI is about to change healthcare. These 42 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.